Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.2% – Still a Buy?

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) rose 3.2% during trading on Friday . The company traded as high as $0.96 and last traded at $0.96. Approximately 263,496 shares were traded during mid-day trading, an increase of 3% from the average daily volume of 256,898 shares. The stock had previously closed at $0.93.

Analyst Ratings Changes

A number of research analysts have recently commented on ONCY shares. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th. Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a research note on Thursday, November 14th.

Oncolytics Biotech Price Performance

The company has a market cap of $74.35 million, a P/E ratio of -3.56 and a beta of 1.63. The stock has a 50-day moving average of $0.97 and a 200 day moving average of $1.01.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.